Physician
Danbury Hospital
Danbury Hospital was paid $15.34M by Medicaid between Jan 2018 and Dec 2024, across 154 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoDANBURY HOSPITAL
NEW MILFORD, CT 06776
NEW MILFORD, CT 06776
33aNPI1619938016assigned 03/28/2006
33bProvider typeEmergency Medicine Physician
28Total paid$15.34M
24GClaims309,666
24DCodes billed154
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Medicine Physician providers in Connecticut
Rank by total paid#2 of 92
Median peer was paid$10K
This provider vs. median1,536×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,342 | $1.67M | |
| 2019 | 40,785 | $1.90M | |
| 2020 | 37,009 | $1.53M | |
| 2021 | 43,358 | $2.19M | |
| 2022 | 46,235 | $2.36M | |
| 2023 | 55,594 | $2.84M | |
| 2024incomplete | 50,343 | $2.85M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 26,238 | 23,123 | $3.74M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 18,550 | 15,849 | $3.29M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 7,177 | 5,981 | $2.44M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.8% | 6,121 | 4,786 | $896K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 2,578 | 2,315 | $519K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.7% | 6,387 | 5,401 | $410K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 3,625 | 3,280 | $410K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.1% | 1,673 | 883 | $320K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.0% | 2,665 | 1,227 | $312K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 4,804 | 3,588 | $276K |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 1.7% | 9,721 | 4,842 | $265K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 5,337 | 3,702 | $255K |
142 more codes
| 99214 | Doctor's office visit, returning patient (more involved) | 1.6% | 2,466 | $242K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 4,270 | $237K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.5% | 3,598 | $223K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 2,167 | $195K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.3% | 1,782 | $193K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.0% | 549 | $157K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 919 | $119K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,971 | $99K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 2,108 | $84K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,234 | $80K |
| 76641 | <1% | 726 | $67K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 599 | $59K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 294 | $44K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 699 | $43K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 44 | $39K |
| 71250 | <1% | 518 | $33K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 169 | $28K |
| 82947 | <1% | 10,473 | $25K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 275 | $20K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,272 | $18K |
| 93975 | <1% | 75 | $17K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 45 | $16K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,646 | $16K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,715 | $13K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 159 | $12K |
| 72100 | <1% | 365 | $12K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 69 | $11K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 397 | $8K |
| 76536 | <1% | 97 | $7K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 92 | $7K |
| 74018 | <1% | 219 | $6K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 41 | $6K |
| 94060 | <1% | 29 | $5K | |
| 73610 | <1% | 481 | $5K | |
| 73030 | <1% | 357 | $5K | |
| 73630 | <1% | 374 | $5K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $4K |
| 98968 | <1% | 119 | $4K | |
| 76830 | Ultrasound, transvaginal | <1% | 43 | $4K |
| 73564 | <1% | 170 | $3K | |
| 80051 | <1% | 7,971 | $3K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 16 | $3K |
| 36592 | <1% | 1,163 | $3K | |
| 96367 | <1% | 44 | $2K | |
| 73130 | <1% | 73 | $2K | |
| 73502 | <1% | 78 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 46 | $2K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,749 | $2K |
| 76770 | <1% | 17 | $2K | |
| 72141 | <1% | 12 | $2K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 17 | $1K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 105 | $1K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 28 | $983.65 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 638 | $802.41 |
| 73110 | <1% | 39 | $572.06 | |
| 80053 | Comprehensive metabolic panel | <1% | 1,323 | $521.90 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 961 | $446.38 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,324 | $401.18 |
| 87400 | <1% | 1,294 | $366.40 | |
| 94726 | <1% | 17 | $331.78 | |
| 96376 | <1% | 699 | $319.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,495 | $310.90 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 618 | $276.12 |
| 87468 | <1% | 219 | $264.68 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,983 | $206.71 |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,472 | $203.34 |
| 82247 | <1% | 6,185 | $196.60 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 247 | $128.77 |
| 84460 | <1% | 6,182 | $119.60 | |
| 84075 | <1% | 6,176 | $105.49 | |
| 84450 | <1% | 6,187 | $101.23 | |
| 82565 | <1% | 11,023 | $99.71 | |
| 86618 | <1% | 531 | $98.90 | |
| 84484 | <1% | 2,882 | $96.79 | |
| J3490 | Unclassified drugs | <1% | 6,200 | $92.50 |
| 84520 | <1% | 10,988 | $89.68 | |
| 87081 | <1% | 387 | $87.85 | |
| 87420 | <1% | 87 | $81.45 | |
| 87469 | <1% | 219 | $77.36 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 455 | $73.58 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,060 | $69.94 |
| 83690 | <1% | 3,691 | $54.65 | |
| 84132 | <1% | 3,040 | $50.32 | |
| 83735 | <1% | 3,156 | $48.84 | |
| 84295 | <1% | 3,035 | $45.93 | |
| 82374 | <1% | 3,034 | $45.93 | |
| 82435 | <1% | 3,035 | $45.93 | |
| 81001 | <1% | 3,465 | $39.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 176 | $35.25 |
| 83880 | <1% | 104 | $33.89 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,266 | $22.05 |
| 84703 | <1% | 2,636 | $16.34 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,170 | $15.64 |
| 76377 | <1% | 634 | $15.05 | |
| 83605 | <1% | 959 | $12.15 | |
| 82310 | <1% | 1,667 | $10.73 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,121 | $9.34 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,170 | $6.53 |
| 81003 | <1% | 2,633 | $5.60 | |
| 82962 | <1% | 1,151 | $5.26 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,742 | $3.84 |
| 84100 | <1% | 279 | $3.23 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 622 | $2.29 |
| 87186 | <1% | 201 | $1.37 | |
| 87077 | <1% | 252 | $1.29 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 197 | $0.60 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 1,579 | $0.00 |
| 81025 | 0% | 75 | $0.00 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 766 | $0.00 |
| 85380 | 0% | 214 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 203 | $0.00 |
| 85610 | 0% | 482 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 71 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 583 | $0.00 |
| 82977 | 0% | 132 | $0.00 | |
| 90714 | 0% | 14 | $0.00 | |
| 86900 | 0% | 14 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 30 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 48 | $0.00 |
| 94729 | 0% | 58 | $0.00 | |
| 73140 | 0% | 13 | $0.00 | |
| 94727 | 0% | 16 | $0.00 | |
| 82077 | 0% | 616 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 1,923 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,690 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 260 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 1,798 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,258 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 264 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 14 | $0.00 |
| G0378 | Hospital observation service, per hour | 0% | 33 | $0.00 |
| 85730 | 0% | 33 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 77 | $0.00 |
| 12001 | 0% | 42 | $0.00 | |
| 99443 | 0% | 16 | $0.00 | |
| 86850 | 0% | 14 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 50 | $0.00 |
| 87040 | 0% | 21 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 57 | $0.00 |
| 82150 | 0% | 12 | $0.00 | |
| 86901 | 0% | 14 | $0.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEBARBA, DANIEL (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Danbury Hospital | Danbury, CT | $123.87M |
| Norwalk Hospital Association | Norwalk, CT | $77.51M |
| Nuvance Health Medical Practice, PC | Poughkeepsie, NY | $15.31M |
| Hudson Valley Cardiovascular Practice, PC | Poughkeepsie, NY | $2.15M |
| Norwalk Hospital Association | Norwalk, CT | $1.93M |
| Western Connecticut Health Network Affiliates, INC. | Danbury, CT | $321K |
| Health Quest Home Care, INC. (Certified) | Poughkeepsie, NY | $200K |
| Western Connecticut Health Network Affiliates, INC. | Ridgefield, CT | $76K |
| Norwalk Hospital Association | Norwalk, CT | $23K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.